Dr. Kris on Dacomitinib in EGFR-Positive Lung Cancer

Mark G. Kris, MD
Published Online: Wednesday, December 12, 2012
Mark G. Kris, MD, chief of the Thoracic Oncology Service at Memorial Sloan-Kettering Cancer Center, discusses the initial trials studying dacomitinib, an irreversible pan-HER tyrosine kinase inhibitor (TKI), in patients with EGFR-mutant lung cancers.

Kris explains that dacomitinib was first studied in hopes that a greater, potentially permanent, tumor shrinkage would occur. A phase II study compared dacomitinib to reversible TKIs such as gefitinib and erlotinib as a first-line treatment for patients with lung cancers. The partial response rate was 74% among patients with EGFR deletions at exons 19 and 21. At one year, progression-free survival (PFS) rate was 77% and median PFS was 17 months.

Dacomitib may be as effective as gefitinib in terms of degree and length of tumor shrinkage, Kris believes.

Online CME Activities
Free CME from PER
Community Practice Connections: 12th Annual International Congress on Targeted Therapies in Cancer®
12th Annual School of Breast Oncology® Online
Advances in Next-Generation Sequencing in Precision Oncology
9th Annual Multidisciplinary Symposium on Head and Neck Cancer® Medical Crossfire®
More Reading
$auto_registration$